Molecular Regulation of Toll-like Receptors in Asthma and COPD

Li Zuo 1,2*, Kurt Lucas 3, Christopher A. Fortuna 1, Chia-Chen Chuang 1,2 and Thomas M. Best 4

1 Radiologic Sciences and Respiratory Therapy Division, The Ohio State University Wexner Medical Center, School of Health and Rehabilitation Sciences, The Ohio State University College of Medicine, Columbus, Ohio State University, Columbus, OH, USA, 2 Interdisciplinary Biophysics Graduate Program, The Ohio State University, Columbus, OH, USA, 3 Multiphase Chemistry Department, Max Planck Institute for Chemistry, Mainz, Germany, 4 Division of Sports Medicine, Department of Family Medicine, Sports Health and Performance Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USA

Asthma and chronic obstructive pulmonary disease (COPD) have both been historically associated with significant morbidity and financial burden. These diseases can be induced by several exogenous factors, such as pathogen-associated molecular patterns (PAMPs) (e.g., allergens and microbes). Endogenous factors, including reactive oxygen species, and damage-associated molecular patterns (DAMPs) recognized by toll-like receptors (TLRs), can also result in airway inflammation. Asthma is characterized by the dominant presence of eosinophils, mast cells, and clusters of differentiation (CD)4+ T cells in the airways, while COPD typically results in the excessive formation of neutrophils, macrophages, and CD8+ T cells in the airways. In both asthma and COPD, in the respiratory tract, TLRs are the primary proteins of interest associated with the innate and adaptive immune responses; hence, multiple treatment options targeting TLRs are being explored in an effort to reduce the severity of the symptoms of these disorders. TLR-mediated pathways for both COPD and asthma have their similarities and differences with regards to cell types and the pro-inflammatory cytotoxins present in the airway. Because of the complex TLR cascade, a variety of treatments have been used to minimize airway hypersensitivity and promote bronchodilation. Although unsuccessful at completely alleviating COPD and severe asthmatic symptoms, new studies are focused on possible targets within the TLR cascade to ameliorate airway inflammation.

Keywords: antioxidant, DAMP, PAMP, polymorphism, reactive oxygen species, TLR

INTRODUCTION

Asthma and chronic obstructive pulmonary disease (COPD) are two respiratory diseases characterized by an accumulation of inflammatory cells in the respiratory tract, which leads to subsequent airflow obstruction (Singh and Busse, 2006; Quint and Wedzicha, 2007). It is estimated that 25 million people in the United States alone are affected by asthma (Centers of Disease Control and Prevention, 2013), and approximately 20 million people are diagnosed with COPD (American Lung Association). Ranking as the third leading cause of death in the United States, COPD shares similar symptomatic features with asthma. However, the mechanisms underlying the pathophysiology of these two diseases are distinct (Barnes, 2008). For instance, the instigators of airway inflammation are different for COPD (neutrophils) and asthma (eosinophils)
(Barnes, 2000). Most notably, patients with COPD experience progressive and irreversible structural alterations, including airway remodeling and alveolar destruction, which ultimately result in breathing difficulties; whereas airway obstruction is often reversible in asthma (Barnes, 2008; Baines et al., 2011). Periodic exacerbations of COPD can worsen respiratory symptoms and markedly increase the risk of mortality (Domej et al., 2014).

Airway inflammation plays an essential role in the development of both asthma and COPD. Undoubtedly, variations in the inflammatory process between the two diseases underlie the unique immunopathologies of asthma and COPD. Emerging evidence suggests that toll-like receptors (TLRs) may be associated with the aberrant stimulation of immune responses, possibly contributing to the chronic inflammation seen in asthma (Phipps et al., 2007). TLRs are a subgroup of pattern recognition receptors (PRRs), which are antigen-sensitive, responsible for innate immunity (Kawai and Akira, 2010). Within the TLR family, there are 10 members that are active in humans (Warren, 2005). Generally, most of these TLRs have been split into two sub-groups. TLR1, TLR2, TLR4, TLR5, TLR6, and TLR11 comprise the first group and are primarily expressed on the cell surface; the function of this group is to recognize the components of microbial membranes (Blasius and Beutler, 2010; Kawai and Akira, 2010). The second sub-group is composed of TLR3, TLR7, TLR8, and TLR9. These TLRs are expressed intracellularly in vesicles (e.g., lysosomes, endosomes, and the endoplasmic reticulum) and can target microbial nucleic acids (Blasius and Beutler, 2010; Kawai and Akira, 2010). Serving as the first line of host defense, the airway epithelium utilizes a variety of receptors, including TLRs, to detect antigens and infectious microorganisms. The lung and respiratory tract are particularly susceptible to pathogens and allergens because of the constant exposure of inhaled air. Additionally, TLRs recognize exogenous pathogen-associated molecular patterns (PAMPs) and host-derived damage-associated molecular patterns (DAMPs; Lafferty et al., 2010). The activation of TLRs through these means selectively induce inflammation, inflammatory cell recruitment, and cytokine release. In particular, TLR2 and TLR4 are regarded as the major TLRs responsible for sustaining the inflammatory responses in both asthma and COPD. However, altering the immunoreactivity and expression of TLRs may result in an impaired immune response, which is marked by abnormal inflammation in the aforementioned diseases (Lafferty et al., 2010). This review will highlight the roles of TLRs in inflammation and their association to the physiopathology of asthma and COPD, as well as discuss the potential for TLR-based treatment of these diseases.

MOLECULAR CHARACTERISTICS OF ASTHMA AND COPD

Persistent inflammation and airflow obstruction are the major characteristics of asthma and COPD. However, the patterns of inflammation and the immunological mechanisms that lead to the airway structural alterations are different for the respective diseases (Barnes, 2000, 2008). Inflammation in the larger conducting airways is mainly observed in asthma. In contrast, COPD predominantly affects the lung parenchyma and smaller airways (Barnes, 2008). Asthma is characterized by the presence of eosinophils, mast cells, and CD4+ T lymphocytes; whereas COPD is distinguished by the dominance of neutrophils, macrophages and CD8+ T lymphocytes in the respiratory tract (Buist, 2003; Baines et al., 2011; Athanazio, 2012). T cell activation is dependent upon the antigen presenting cells (e.g., dendritic cells) and plays a substantial role in inflammation (Shalaby and Martin, 2010).

In asthma, IgE binds to receptors found on the surface of mast cells, thus initiating an allergic response (Gauvreau et al., 2015). The recruited mast cells subsequently degranulate to release histamine, an organic compound known to increase hypersensitivity and inflammation, thereby leading to the development of bronchoconstriction (Figure 1; Jutel et al., 2009). Bronchoconstriction is both spontaneous and reversible in asthmatics, and is induced by the hyperreactive smooth muscle surrounding the bronchioles (Athanazio, 2012). Moreover, structural changes, such as subepithelial fibrosis and smooth muscle cell hyperplasia and hypertrophy, can contribute to the thickening of asthmatic airways (Barnes, 2008). In most asthma cases, there is a predominant expression of Th2-type cytokines, including interleukin (IL)-4, IL-5, and IL-13, which are all activated by the transcription factor GATA-binding protein 3 (GATA3; Zhu et al., 2006). These Th2-type cytokines result in the increased migration of eosinophils and mast cells. One of the consequences of eosinophilic inflammation is epithelial shedding, which is frequently observed in biopsies from asthmatic patients (Barnes, 2000).

Interestingly, the activation of mast cells is not evident in patients with COPD (Barnes, 2008). Instead, macrophages are recruited to the COPD airway via the release of the cytokine interferon γ (IFN-γ) by either CD4+ T cells or Th1 cells (Barnes, 2004). The reduction in airway capacity originates from cellular damage found in COPD. Several initiators can cause this destruction, including exposure to noxious particles, such as cigarette smoke and exogenous reactive oxygen species (ROS; Zuo et al., 2014). In addition to IFN-γ, other major cytokines expressed in COPD are IL-1, IL-8 (also known as CXCL8), leukotriene B4, granulocyte-macrophage colony-stimulating factor (GM-CSF), and tumor necrosis factor-α (TNF-α) (Kim and Rhee, 2010; Athanazio, 2012). The expression of IFN-γ, IL-8, GM-CSF, and TNF-α lead to the activation and migration of neutrophils to the airways (Figure 1; Wright et al., 2010). Moreover, COPD differs from asthma in the expression of certain TLRs. For instance, in asthma, the presence of TLR4 is lowered in the respiratory tract, whereas TLR4 expression is elevated in COPD patients, possibly as a result of the cellular breakdown in the airways (Bezemer et al., 2012).

ROLE OF TLR DURING INFLAMMATION

The epithelium of the respiratory tract contains a myriad of TLRs, which participates in the activation of immune responses. Particularly, the role of specific TLRs during inflammation...
has suggested their involvement in the pathogenesis of asthma and COPD (Lafferty et al., 2010). TLRs are also expressed in resident lung cells, such as alveolar macrophages, and other infiltrating cells (Lafferty et al., 2010). TLR4-expressing fibroblasts and epithelial cells have been found to contribute to the localized inflammatory response (Buckley, 2011). These cells have an anchor-like function, utilizing their ability to attract and immobilize leukocytes through the release of several chemokines and cellular adhesion molecules (Buckley et al., 2001). When the leukocytes persist in the respiratory tract, chronic inflammation is an expected outcome (Buckley et al., 2001; Buckley, 2011).

### Inflammatory Aspects of Asthma

TLR2 and TLR4 are the most relevant to the onset of asthma and to the inflammatory responses underlying asthmatic exacerbations. TLR4 detects Gram-negative bacteria through their lipopolysaccharides (LPS; Lafferty et al., 2010), while TLR2 plays a large role in recognizing Gram-positive bacteria (Jiang et al., 2006). As described earlier, Th2 cells, mast cells, and eosinophils are commonly associated with the innate and adaptive immune responses in asthma (Figure 1; Walsh et al., 2010). The recognition of allergens, such as house dust mites (HDM), can activate TLR4 and subsequently allergen-specific Th2 cells (Lafferty et al., 2010). TLR2 promotes Th2-biased immune responses, which may be correlated to the Th1/Th2 imbalance in asthma (Phipps et al., 2007). There are two distinct pathways in TLR signaling: myeloid differentiation factor 88 (MyD88)-dependent and MyD88-independent. Both pathways are crucial in regard to the innate immune response. MyD88 and Toll/IL-1 receptor-domain containing adapter-inducing interferon-β (TRIF) bind independently to TLRs, leading to the release of cytokines such as TNF-α, IL-1β, CXCL10, IL-6, and IFN-γ (Piras and Selvarajoo, 2014). During acute asthmatic exacerbations, the cleavage products of proteinases, such as fibrinogen, bind to TLR4s that are present in both the airway epithelium and macrophages, and the binding of these products results in allergic inflammation (Millien et al., 2013). In addition, asthmatic patients who ultimately die have increased expressions of TLR2, TLR3, and TLR4, suggesting their potential role in the development of severe or even fatal asthmatic exacerbations (Kim and Rhee, 2010; Ferreira et al., 2012).

### Genetic Factors in Asthma

Genetic polymorphisms play a significant role in how individuals respond to diseases. The genetic make-up of a person can make
them more or less susceptible to a specific disease (Lee et al., 2012). Similarly, genetic polymorphisms affect the susceptibility, severity, and responsiveness of asthmatic patients to specific allergens. Variants of the TLR4 gene may either increase or decrease the sensitivity of the receptor to allergens (Cho et al., 2011). Zhang et al. indicated that polymorphisms in TLR4 have an impact on the responsiveness of the receptor to pathogens (Zhang et al., 2011). During this study, several types of polymorphisms were examined in an attempt to discover the particular combination of genes responsible for the susceptibility and severity of asthma. The TT homozygote allele of the TLR gene rs1927914 has deleterious effects for the forced expiratory volume in 1 s (FEV1) (Zhang et al., 2011). A decreased FEV1 suggests a reduced lung capacity and increased airway resistance. Furthermore, the C allele of rs1927914 and the A allele of both rs10983755 and rs1927907 lessen the severity of asthma (Zhang et al., 2011). In addition to TLR4, polymorphisms present in the TLR2 gene are also associated with the risk of asthma development and overall lung function (Gao et al., 2013). The genotype of the TT variant of the homozgyous polymorphism rs7656411 in TLR2 may reduce the incidence of asthma (Qian et al., 2010). It has been shown that the T allele of the rs2381289 single nucleotide polymorphism (SNP) in TLR6 contributes to the development of allergic rhinitis and asthma, while the A allele of rs11466651 SNP in TLR10 is negatively associated with asthma development (Qian et al., 2010).

**Inflammatory Aspects of COPD**

Several TLRs, including TLR2, TLR4, and TLR9, participate in the pathogenesis of COPD. The major risk factors associated with COPD development include cigarette smoking and the inhalation of air pollutants (Bezemer et al., 2012). There is a high correlation between cigarette smoke exposure and the increased gene expression of TLR4 and TLR9 as well as cytokine overproduction (Nadigel et al., 2011; Bezemer et al., 2012; Freeman et al., 2013). Both TLR4 and TLR9 have been shown to contribute to the release of IL-8 from CD8+ T cells (Nadigel et al., 2011). Through the upregulation of IL-8, TLR9 elicits an inflammatory response by initiating neutrophil recruitment (József et al., 2006; Mortaz et al., 2010). It is also known that TLR4 deficiency promotes emphysema (An et al., 2012). When exposed to cigarette smoke, alveolar apoptosis increased in TLR4-deficient mice, suggesting a protective role of TLR4 in cell regulation and apoptosis prevention (An et al., 2012). Interestingly, mice that lack TLR4 expression are more susceptible to oxidative stress due to an upregulation of NADPH oxidase (Nox) 3 (Zhang et al., 2006; Kamprath et al., 2011). It was proposed by Zhang et al. that TLR4 acts as a suppressor of Nox3, therefore regulating the release of ROS (Zhang et al., 2006). Thus, it is possible that in the absence of TLR4, ROS reaches harmful levels and ultimately leads to cellular apoptosis and emphysema. Experimentally, emphysema progression in TLR4-deficient mice can be halted by a Nox inhibitor or Nox3 siRNA (Zhang et al., 2006). Furthermore, a dramatic decrease in antioxidant activity, particularly glutathione levels, was observed in TLR4 knockout mice (Zhang et al., 2006).

Additionally, TLRs are considerably involved with exacerbations of COPD. Research has indicated that MyD88 works in conjunction with TLR4 to upregulate IL kinases and increase IL production (Doz et al., 2008). The interactions between MyD88, TLR4 and IL-1 receptor type I (IL1R1) can lead to acute lung inflammation in COPD patients. Moreover, neutrophil recruitment due to cigarette smoke exposure is dependent on TLR4/MyD88/IL1R1 signaling (Doz et al., 2008; Sarir et al., 2008). TLR2 and TLR4 are the primary mediators that elicit immune responses to microbial invasion in the respiratory tract (Figure 1; Oliveira-Nascimento et al., 2012).

Patients with COPD have increased TLR1 and TLR2 expression on CD8+ T cells and which may contribute to lung damage and alveolar destruction (Freeman et al., 2013). However, it was also discovered that LPS-induced TLR4 expression is reduced in the lymphocytes of smokers with and without COPD (Knobloch et al., 2011). Therefore, a thorough examination of immune cells and the expression of specific TLRs are needed in future research.

**Genetic Factors in COPD**

Several polymorphisms are known to influence the likelihood of developing COPD. In particular, SNPs have been shown to impair TLR signaling by reducing the responsiveness of TLRs and the resistance to bacteria and viruses (Cheng et al., 2007; Bronkhorst et al., 2013). Previous research has indicated that the presence of the TLR4-T3991 polymorphism increases the risk for COPD development by a factor of 2.4 (Speletas et al., 2009). Several SNPs present in TLR2 are highly associated with lung function. Accordingly, Budulac et al. suggested that both TLR2 SNPs (rs1898830 and rs11938228) are involved in FEV1 decline, whereas the SNPs rs7656411 and rs4696480 are related to increased FEV1 (Budulac et al., 2012). The TLR2 SNP rs11938228 may be responsible for an acute increase in neutrophils and macrophages. Likewise, the SNPs rs12377632 and rs10759931 in TLR4 are highly associated with inflammation in the lung and respiratory tracts (Budulac et al., 2012). These studies confirm the association between specific polymorphisms and COPD, warranting additional investigations of this area.

**ROLE OF ROS IN TLR REGULATION IN ASTHMA AND COPD**

The accumulation of ROS is also evident in patients with COPD and asthma (Zuo et al., 2012, 2013). ROS are beneficial during inflammatory responses, as their presence aids in the destruction of microbes. However, excessive ROS can directly initiate inflammatory responses and negatively affect tissue functions and cellular structures, including DNA and lipids (Figure 1; Kirkham and Rahman, 2006; Zuo et al., 2011a, b, 2015). These oxidants are produced endogenously by mitochondria, NADPH oxidase, phagocytes, and lymphocytes, or exogenously from sources such as cigarette smoke and ozone (Zuo et al., 2011c; Hernandez et al., 2012). The overproduction of ROS may lead to inflammation via the activation of transcription factors such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB; Rahman, 2006). In addition, ROS can alter the conformation of proteins, which then may bind to antibodies.
and generate a false immune response, promoting smooth muscle cell hyperactivity via calcium influx (Tetley, 2005; Kirkham et al., 2011). ROS also stimulate TLR2 and TLR4 through MyD88-dependent pathways, inducing cellular damage and elevated levels of DAMPs (Hansel and Barnes, 2009). Furthermore, oxidative stress contributes to the sensitization of allergens by generating an enhanced allergic immune response (Shalaby et al., 2013), thus exacerbating the development of allergic asthma. The presence of ROS in the innate immune response is intended to destroy invading pathogens, yet it may generate undesired cellular damage (Figure 1; Quinn and Schepetkin, 2009; Delfino et al., 2011).

**TLR-BASED THERAPY FOR ASThma AND COPD**

As reported by the Mayo Clinic, the typical treatment for asthma exacerbations includes the inhalation of corticosteroids (Townley and Sulaiman, 1987). In the treatment of COPD, a combination of long-acting bronchodilators and inhaled corticosteroids is typically used (Wedzicha et al., 2012). Corticosteroids are known to enhance β-adrenergic responses and repress inflammatory responses in the airway (Tamm et al., 2012). However, in severe cases of asthma and COPD, corticosteroids are ineffective in alleviating symptoms (Kirkham and Rahman, 2006; Brusselle et al., 2011; Barnes, 2013). This is likely due to overwhelming oxidative stress and subsequent DNA damage, leading to decreased activity of transcriptional co-repressors such as histone deacetylase-2 (HDAC-2) (Kirkham and Rahman, 2006).

Therefore, antioxidant treatments may reduce the production of DAMPs by scavenging ROS and consequently inhibiting the activation of more TLRs (Kirkham and Rahman, 2006).

Drugs that target TLRs can be classified as either agonists or antagonists. TLR agonists increase the response of receptors, while antagonists generally mitigate the responses by attenuating inflammation (Xiang et al., 2010). In allergic asthma, chronic inflammation is caused by exposure to allergens. In asthma treatment, antagonists targeting muscarinic receptors are used to relax the smooth muscle of the airway to promote bronchodilation (Barnes, 2006; Moulton and Fryer, 2011). Shalaby et al. observed that an intranasal administration of Protilolin, a compound composed of both TLR2 and TLR4 ligands, is effective in inhibiting allergic responses (Shalaby et al., 2012). Another study conducted by Xirakia et al. showed that the administration of a compound commonly known as Resiquimod or R-848, a TLR7 agonist, was beneficial in the suppression of allergic airway diseases (Xirakia et al., 2010). TLR7 has anti-inflammatory characteristics, and its activation is known to curb inflammation through the reduction of leukocytes entering the airways. Most notably, R-848 diminishes leukocyte recruitment, as well as the production of IL-5 and IL-13 (Drake et al., 2012). The protective mechanisms of TLRs are thought to arise from the reorientation of the immune system to reduce TH2 function, including the production of TH2 cytokines, eosinophils, and bronchial hypersensitivity, resulting in decreased airway inflammation (Aumeunier et al., 2010; Xirakia et al., 2010).

**KEY STUDIES IN TLRs—AN UPDATE FROM 2010 TO 2014**

TLRs have become a protein of interest and are accepted as a major site for transmitting inflammatory responses in the mucosal lining of the lungs and nasal pathways (Lafferty et al., 2010). However, the activation of the innate immunity in the nasal and lung mucosa is TLR- and PAMP-specific. Ryu et al. observed that HDM-derived β-glucans trigger innate immune responses in the nasal mucosa of mice via TLR2, whereas LPS induces TLR4 signaling in the mucosa of the lower respiratory region (Ryu et al., 2013). The study also found that dual oxidase 2-generated ROS regulates the activation of the β-glucan-induced TLR2 pathway and the LPS-TLR4 interaction (Ryu et al., 2013). The interaction consists of the Toll/IL1R homology (TIR) domain made of the accessory protein CD14, which binds to LPS, TLR4, and MD2 protein. Once LPS is bound, the TIR domain communicates with MyD88 to further relay several kinase activations, such as IL-1 receptor kinase (IRAK), until a response is triggered (Park and Lee, 2013). Collectively, these findings suggest a promising role for TLRs in the treatment of both allergic rhinitis and asthma.

Lucas et al. suggested that TLRs play a pathogenic role in the development of many human diseases, including cardiovascular disease, Parkinson's disease, and asthma (Lucas and Maes, 2013b). Additionally, the study examined several methods that attempt to neutralize the effects of TLRs in disease development (Lucas and Maes, 2013b). Several different PAMPs and DAMPs can be recognized by specific TLRs. For instance, the interaction that occurs between LPS and TLR4 involves the binding of LPS to CD14, an accessory protein of TLR4. LPS is then transferred to myeloid differential protein-2, another TLR4 accessory molecule, initiating the downstream signaling pathway of TLR4 (Lucas and Maes, 2013b). Other factors known to affect the TLR pathways were also discussed, including ozone, particular matter, bacteria and viruses, aerosol particles, certain metals, adjuvants, vaccines, pesticides, preservatives, ionizing radiation, inhaled toluene, TLR adaptations, ROS, and Oxidized 1-palmitoyl-2-araachidonyl-sn-3 (OxPAPC; Lucas and Maes, 2013b). Synthetic anti-LPS peptides (SALPs) have been developed as treatments that target LPS. SALPs bind to LPS and prevent TLR4 activation, thereby attenuating the host inflammatory response (Lucas and Maes, 2013b). These SALPs are useful because they effectively neutralize endotoxins at low concentrations, preventing endotoxic shock. There are several antagonists known to suppress the MyD88-dependent and -independent pathways by inhibiting the TANK-binding kinase 1 (TBK1), including compounds found in common traditional Chinese medicines, such as green tea and ginger (Lucas and Maes, 2013b). Targeting the MyD88 pathway may provide potential treatment options because all TLRs, except TLR3, depend on this pathway. Antioxidant treatments, such as N-acetyl-L-cysteine (NAC) and flavonoids, scavenge excess ROS, further reducing the formation of DAMPs (Lucas and Maes, 2013b). By modulating the responsiveness of TLRs through antioxidants, multiple TLR-dependent human diseases may be significantly improved (Lucas and Maes, 2013b). TLR4 antagonists can target the TLR radical
cycle. Interestingly, several plants used in traditional Chinese medicine were used to optimize the TLR radical cycle effects (Table 1).

Table 1

| Plants/Pharmacologically active substances | Effects | Citations |
|-------------------------------------------|---------|-----------|
| Green Tea (Camellia sinensis) Epigallocatechin gallate | Potent antioxidant | Shirai et al., 2003; Wu et al., 2012; Bao et al., 2014 |
| Turmeric (Curcuma longa) Curcumin | Prevents accumulation of inflammatory cells in airways | Oh et al., 2011; Ma et al., 2013; Chauhan et al., 2014 |
| Cinnamaldehyde, cinnamic acid, and cinnamate | Lowers expression of TLR4, MyD88 and NF-κB | Shen et al., 2012; Lucas and Maes, 2013a |
| Ginger (Zingiber officinalis)/6-gingerol, 8-gingerol, 6-shogaol | Anti-inflammatory by modulation of STAT3 and MAPKs signaling pathways | Townsend et al., 2013; Prasad and Aggarwal, 2014; Yoshida et al., 2014 |
| Xing-ren (Semen Armeniacae Amurem)/(Amgyladin | Inhibits expression of TLR4 and IL-1β | Huang et al., 2013 |
| Xinjiang liquorice, (Glycyrrhiza inflata), Flavonoids | Attenuation of allergic airway inflammation | Chu et al., 2013; Fu et al., 2013 |

1Lucochalcone A, 5-(1,1-Dimethylallyl)-3,4′,6-trihydroxy-2-methoxychalcone, Licochalcone B, Echinatin, Glycyoursamin, Glycuralin B.

AR, aryhydrocarbon receptor; Ca2+, calcium ion; IL, interleukin; MAPK, mitogen-activated protein kinase; MyD88, myeloid differentiation primary response gene (88); STAT3, signal transducer and activator of transcription 3; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; Th17, T helper 17 cell; TLR, toll-like receptor; TNF-α, tumor necrosis factor alpha; Treg, regulatory T cell.

The ongoing cycle is controlled by multiple factors, and there is no clear initiation or termination. The cycle provides a multitude of targets ranging from TLRs to oxidative radicals for suppressing the immune response. Further research is needed to determine which of these could translate into effective treatment approaches.

TLR5 and TLR7 are epithelial receptors that have both been shown to participate in respiratory inflammation (Shikhagaie et al., 2014). Specifically, TLR5 aids in the detection of bacterial flagellin protein, a component of flagellated bacteria, and enhances flagellin-specific CD4+ T cell responses and adaptive immunity (Letran et al., 2011). In addition, TLR7 represses host inflammatory responses by promoting bronchodilation, as well as decreasing airway hyperreactivity and inflammation (Drake et al., 2012). The expressions of TLR5 and TLR7 are decreased in the epithelium of patients with severe asthma compared with healthy individuals and those with moderate asthma. This decreased expression may affect the innate immune response (Shikhagaie et al., 2014). Metcalfe et al. studied the effects of several PAMPs on TLR expression in alveolar macrophages in patients with COPD, such as cigarette smoke extract (CSE), common LPS, Pam3CSK4, and phase 1 flagellin (FlhC) (Metcalfe et al., 2014). The study found that CSE suppressed the TLR-induced production of TNF-α, IL-6, and IL-10. However, IL-8 production was unaffected. An analysis of gene expression illustrated that CSE inhibited LPS-activated TNF-α transcription but did not affect the transcription of IL-8 in alveolar macrophages. This attenuating effect has been correlated to a decreased activation of p38, p65, and extracellular signal regulated kinase (ERK) (Metcalfe et al., 2014).
POTENTIAL THERAPEUTICS TARGETING INFLAMMATION AND ROS

Considering ROS formation is common in asthma and COPD, the use of free radical scavengers, such as resveratrol, NAC, hydrogen sulfide (H₂S), and molecular hydrogen (H₂), may be an effective adjuvant treatment (Kirkham and Rahman, 2006; Ohta, 2011; Wang et al., 2012; Jiang et al., 2014). For instance, airway hyperreactivity can be alleviated by NAC treatment (Carlsten et al., 2014). In an animal model of allergic asthma, the administration of NAC attenuated airway hyperresponsiveness induced by birch pollens (Shalaby et al., 2013). In addition, immune responses initiated by diesel exhaust exposure can be diminished via NAC supplementation (Carlsten et al., 2014). In an animal model for allergic asthma, resveratrol, a well-known flavonoid, restored inositol polyphosphate 4 phosphatase (INPP4A) activity and thus reduced allergic reactions (Aich et al., 2012). This compound interacts with the aryl hydrocarbon receptor (AhR), which can downregulate the expression of pro-inflammatory genes (Revel et al., 2003). H₂S is another plausible target for the treatment of asthma because it may serve as a molecular marker for asthma, it could be used as a therapeutic gas, and it may act as both a hormone and a neurotransmitter in the human body (Farrugia and Szurszewski, 2014; Lo Faro et al., 2014). H₂S can relax the smooth muscle in intrapulmonary airways by inhibiting intracellular Ca²⁺ release (Castro-Piedras and Perez-Zoghbi, 2013). On the other hand, H₂S exhibits antioxidant and anti-inflammatory characteristics (Zhang et al., 2013). For example, exogenous H₂S can reverse ovalbumin-induced asthma (Zhang et al., 2013). The concentration of H₂S is increased in the sputum supernatants and the serum of asthma patients, while lung function is found to be inversely correlated with H₂S levels in sputum (Chung, 2014). Therefore, it is possible that H₂S may serve as a molecular marker in patients diagnosed with asthma (Chung, 2014).

Interestingly, H₂ appears to be another effective ROS scavenging drug (Ohno et al., 2012). In a rat model of COPD, the beneficial effects of the injection of H₂-enriched water included reduced mucus production and epithelium damage, partly associated with the scavenging of free radicals by H₂ (Ning et al., 2013). The positive effects of H₂-enriched saline have been reproduced in animal models of asthma (Xiao et al., 2013). Xiao et al. demonstrated that the application of saline enriched with H₂ can attenuate the NFκB pathway, an important part of the TLR radical cycle (Xiao et al., 2013). Thus, the inhalation of gaseous H₂ may be a viable treatment option for patients with asthma and/or COPD.

CONCLUSION

Current research has shown the significance of TLRs in the pathogenesis of respiratory diseases, such as asthma and COPD. The role of TLRs in the immune response has been well-documented, and polymorphisms of the TLR genes can result in drastic changes in the severity and susceptibility of respiratory inflammatory diseases. Several treatments targeting the TLR pathway have been topics of ongoing research in an attempt to minimize the severity of both diseases. Studies relating to asthma mostly show a higher degree of activation of the TLR radical cycle. In contrast, this cycle seems to collapse in COPD subjects. Thus, antagonists of TLRs and anti-inflammatory drugs may have beneficial effects in patients with asthma but not in those with COPD. However, antioxidant therapies may be beneficial in both diseases. Further research is necessary to explore the realm of TLR-based treatments, as these molecules play a significant role in the development and ongoing symptoms associated with asthma and COPD.

ACKNOWLEDGMENTS

We acknowledge the assistance of Benjamin Pannell, Annie Wang, Andrew Graef, Tingyang Zhou, Ethan Range, Benjamin Hemmelgarn, Alexander Ziegler, and Jiewen Li during the preparation of this manuscript.
REFERENCES

Aich, J., Mabalirajan, U., Ahmad, T., Khanna, K., Rehan, R., Agrawal, A., et al. (2012). Resveratrol attenuates experimental allergic asthma in mice by restoring inositol polyphosphate 4 phosphate (INPP4A). *Int. Immunopharmacol.* 14, 438–443. doi: 10.1016/j.intimp.2012.08.017

An, C. H., Wang, X. M., Lam, H. C., Icedigbo, E., Washko, G. R., Ryter, S. W., et al. (2012). TLR4 deficiency promotes autophagy during cigarette smoke-induced pulmonary emphysema. *Am. J. Physiol. Lung Cell. Mol. Physiol.* 303, L748–L757. doi: 10.1152/ajplung.00102.2012

Athanazio, R. (2012). Airway disease: similarities and differences between asthma, COPD and bronchiectasis. *Clinics (Sao Paulo)* 67, 1335–1343. doi: 10.6061/clinics/2012(11)19

Aumeunier, A., Grela, F., Ramadan, A., Pham Van, L., Bardel, E., Gomez Alcala, A., et al. (2012). Systemic Toll-like receptor stimulation suppresses experimental allergic asthma and autoimmune diabetes in NOD mice. *PLoS ONE* 7:e41184. doi: 10.1371/journal.pone.0011484

Bachi, A., Dalle-Donne, I., and Scalon, A. (2013). Redox proteomics: chemical principles, methodological approaches and biological/biomedical promises. *Chem. Rev.* 113, 596–698. doi: 10.1021/cr300073p

Baines, K. J., Simpson, J. L., and Gibson, P. G. (2011). Innate immune responses and chronic obstructive pulmonary disease. *Br. J. Pharmacol.* 164, 337–358. doi: 10.1111/j.1440-2440.2011.06053.x

Barnes, P. J. (2000). Mechanisms in COPD: differences from asthma. *Chest* 117, 18S–25S. doi: 10.1378/chest.117.2_suppl.18S

Barnes, P. J. (2004). Mediators of chronic obstructive pulmonary disease. *Pharmacol. Rev.* 56, 515–548. doi: 10.1124/pr.56.4.2

Barnes, P. J. (2006). Drugs for asthma. *Br. J. Pharmacol.* 148(Suppl. 1), S1–S12. doi: 10.1210/jbr.2004-2810

Barnes, P. J. (2012). Airway cells from atopic asthmatic patients exposed to ozone display an enhanced innate immune gene profile. *J. Allergy Clin. Immunol.* 130, 516–521. doi: 10.1016/j.jaci.2012.04.038

Barnes, P. J., Akbar, A. N., Pilling, D., Lord, J. M., Scheel-Toellner, D., and Buckley, C. D. (2010). Toll-like receptor (TLR2 and TLR4) polymorphisms and chronic obstructive pulmonary disease. *PLoS ONE* 5:e134124. doi: 10.1371/journal.pone.0043124

Bezemer, G. F., Sagar, S., Van Bergenhenegouwen, J., Georgiou, A. N., Garssen, J., and Beutler, B. (2010). Intracellular toll-like receptors. *Thromb. Haemost.* 103, 730–741. doi: 10.1160/TH10-03-0186

Buckley, C. D., Pilling, D., Lord, J. M., Akbar, A. N., Scheel-Toellner, D., and Salmon, M. (2001). Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. *Trends Immunol.* 22, 199–204. doi: 10.1016/S1471-4906(01)00863-4

Buckley, C. D. (2011). Why does chronic inflammation persist: an unexpected role for fibroblasts. *Immunol. Lett.* 138, 12–14. doi: 10.1016/j.imlet.2011.02.010

Castro-Piedras, I., and Perez-Zoghbi, J. F. (2013). Hydrogen sulphide inhibits Ca2+ release through InsP3 receptors and relaxes airway smooth muscle. *J. Physiol.* 591, 5999–6015. doi: 10.1113/jphysiol.2013.257790

Delfino, R. J., Staimer, N., and Vaziri, N. D. (2011). Air pollution and circulating biomarkers of oxidative stress. *Air Qual. Atmos. Health* 4, 37–52. doi: 10.1007/s11869-010-0095-2

Dove, E., Oettl, K., and Renner, W. (2014). Oxidative stress and free radicals in COPD — implications and relevance for treatment. *Int. J. Chron. Obstruct. Pulmonal Dis.* 9, 1207–1224. doi: 10.2147/COPD.S51226

Drake, M. G., Kaufman, E. H., Fryer, A. D., and Jacoby, D. B. (2012). The therapeutic potential of Toll-like receptor 7 stimulation in asthma. *Inflamm. Allergy Drug Targets* 11, 484–491. doi: 10.2174/187152811083399869

Efrat, A., and Shani, A. (2000). The role of the innate immune system in the pathogenesis of COPD. *Eur. Respir. J.* 16, 1060–1066. doi: 10.1183/09031936.00040903

Ferreira, D. S., Annoni, R., Silva, L. F., Buttignol, M., Santos, A. B., Medeiros, M. C., et al. (2012). Toll-like receptors 2, 3 and 4 and thymic stromal lymphopoietin expression in fatal asthma. *Clin. Exp. Allergy* 42, 1459–1471. doi: 10.1111/j.1365-2222.2012.04047.x

Fischer, S., Grantzow, T., Pagel, J. I., Tschernatsch, M., Sparrlian, M., Preissner, K. T., et al. (2012). Extracellular RNA promotes leukocyte recruitment in the vascular system by mobilising proinflammatory cytokines. *Thromb. Haemost.* 108, 730–741. doi: 10.1160/TH11-03-0186

Freeman, C. M., Martinez, F. J., Han, M. K., Washko, G. R. Jr., McCubbrey, A. L., Chensue, S. W., et al. (2013). Lung CD8+ T cells in COPD have increased expression of bacterial TLRs. *Respir. Res.* 14:13. doi: 10.1186/1465-9921-14-13

Fu, Y., Chen, J., Li, Y. J., Zheng, Y. F., and Li, P. (2013). Antioxidant and anti-inflammatory activities of six flavonoids separated from llicorice. *Food Chem.* 141, 1063–1071. doi: 10.1016/j.foodchem.2013.03.089

Gao, Z., Dosman, J. A., Schwartz, D. A., Yang, I. V., Beach, J., and Dosman, J. A. (2013). Characteristics of traditional Chinese medicine use in children with asthma. *Ann. Allergy Asthma Immunol.* 110, 545–550. doi: 10.1111/j.1399-3003.2012.05365.x

Hansel, T. T., and Barnes, P. J. (2009). New drugs for exacerbations of chronic obstructive pulmonary disease. *Lancet* 374, 744–755. doi: 10.1016/S0140-6736(13)61342-8

Hernandez, M., Brickey, W. J., Alexis, N. E., Fry, R. C., Rager, J. E., Zhou, B., et al. (2012). Airway cells from atopic asthmatic patients exposed to ozone display an enhanced innate immune gene profile. *J. Allergy Clin. Immunol.* 129, 259–261. doi: 10.1016/j.jaci.2011.07.007

Huang, T. P., Liu, P. H., Lien, A. S., Yang, S. L., Chang, H. H., and Yen, H. R. (2013). Characteristics of traditional Chinese medicine use in children with Co
Knobloch, J., Schild, K., Jungck, D., Urban, K., Müller, K., Scheda, E. K., et al.
Lafferty, E. I., Qureshi, S. T., and Schnare, M. (2010). The role of toll-like receptors in non-infectious lung injury. Cell Res. 16, 693–701. doi: 10.1038/cr.2006.35
Jiang, L., Diaz, P. T., Best, T. M., Stimpfl, J. J., Ne, F., and Zuo, L. (2014). Molecular characterization of redox mechanisms in allergic asthma. Ann. Allergy. Asthma Immunol. 113, 137–142. doi: 10.1016/j.anai.2014.05.030
Jössef, L., Kheissi, T., El Kebir, D., and Fjell, J. G. (2006). Activation of TLR-9 induces IL-8 secretion through peroxysynitrile signalan in human neutrophils. J. Immunol. 176, 1195–1202. doi: 10.4049/jimmunol.176.2.1195
Jutel, M., Akdis, M., and Akdis, C. A. (2009). Histamine, histamine receptors and their role in immune pathology. Clin. Exp. Allergy 39, 1786–1800. doi: 10.1111/j.1365-2318.2009.02820.x
Kadl, A., Sharma, P. R., Chen, W., Agrawal, R., Meher, A. K., Rudraiah, S., et al. (2011). Oxidized phospholipid-induced inflammation is mediated by Toll-like receptor 2. Free Radic. Biol. Med. 51, 1903–1909. doi: 10.1016/j.freeradbiomed.2011.08.026
Kampfrath, T., Maiseyuz, A., Ying, Z., Shah, Z., Deulilis, J. A., Xu, X., et al. (2011). Chronic fine particulate matter exposure induces systemic vascular dysfunction via NADPH oxidase and TLR4 pathways. Circ. Res. 108, 716–726. doi: 10.1161/CIRCRESAHA.110.237560
Kawai, T., and Akira, S. (2010). The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373–384. doi: 10.1038/ni.1863
Kim, S. R., and Rhee, Y. K. (2010). Overlap between asthma and COPD: where the two diseases converge. Allergy Asthma Immunol. Res. 2, 209–214. doi: 10.4168/aair.2010.2.4.209
Kirkham, P. A., Caramori, G., Casolari, P., Papi, A. A., Edwards, M., Shamji, B., Kawai, T., and Akira, S. (2010). The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373–384. doi: 10.1038/ni.1863
Ko, L. K., and Rhee, Y. K. (2010). Oxidized stress and airway remodeling in asthma. Am. J. Respir. Crit. Care Med. 181, 1175–1182. doi: 10.1164/rccm.200910-1605OC
Ko, L. K., and Rhee, Y. K. (2010). Oxidized stress and airway remodeling in asthma. Am. J. Respir. Crit. Care Med. 181, 1175–1182. doi: 10.1164/rccm.200910-1605OC
Ko, L. K., and Rhee, Y. K. (2010). Oxidized stress and airway remodeling in asthma. Am. J. Respir. Crit. Care Med. 181, 1175–1182. doi: 10.1164/rccm.200910-1605OC
Ko, L. K., and Rhee, Y. K. (2010). Oxidized stress and airway remodeling in asthma. Am. J. Respir. Crit. Care Med. 181, 1175–1182. doi: 10.1164/rccm.200910-1605OC
Ko, L. K., and Rhee, Y. K. (2010). Oxidized stress and airway remodeling in asthma. Am. J. Respir. Crit. Care Med. 181, 1175–1182. doi: 10.1164/rccm.200910-1605OC
Ko, L. K., and Rhee, Y. K. (2010). Oxidized stress and airway remodeling in asthma. Am. J. Respir. Crit. Care Med. 181, 1175–1182. doi: 10.1164/rccm.200910-1605OC
Ko, L. K., and Rhee, Y. K. (2010). Oxidized stress and airway remodeling in asthma. Am. J. Respir. Crit. Care Med. 181, 1175–1182. doi: 10.1164/rccm.200910-1605OC
